MRIA9 is an ATP-competitive, pan Salt-Inducible kinase (SIK) and PAK2/3 inhibitor, with IC 50 values of 516 nM, 180 nM and 127 nM for SIK1 , SIK2 and SIK3 , respectively In Vitro MRIA9 (5 μM) MRIA9 sensitizes SKOV3 cells to paclitaxel treatment through inducing pronounced apoptosis. MRIA9 (5 μM) with paclitaxel (2 nM) significantly enhances cell death in HeLa cells. MRIA9 strongly impedes centrosome function, causes mitotic spindle mispositioning in ovarian cancer cell lines, prevents the centrosome disjunction during the late G2 phase, and sensitized ovarian cancer cells and patient derived 3D-spheroids to paclitaxel treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SKOV3 cells. Concentration: 0.5-5 μM (1 nM paclitaxel). Incubation Time: 9 days. Result: Inhibited cell growth. In Vivo MRIA9 shows high oral bioavailability (F = 75-80%) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:SIK1 SIK2 SIK3
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
MRIA9
CAS number：2750707-05-0 molecular formula：C24H22ClFN6O3
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2750707-05-0 | molecular formula | C24H22ClFN6O3 |
| molecular weight | 496.92 g/mol | Exact mass | ≥98% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
